A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients with Solid Tumors Likely to Express CLDN18.2 November 7, 2023
A First-in-Human, Open-Label, Multi-Center Phase 1 Study of TST003 in Subjects with Locally Advanced or Metastatic Solid Tumors November 7, 2023